Evora Biosciences

Evora Biosciences is a private, preclinical-stage biotech pioneering a novel therapeutic class of immunomodulatory lipopeptides. Its EVO platform aims to generate stable, non-toxic compounds with selective anti-inflammatory effects, positioning them as potential standalone or steroid-sparing treatments in high-need inflammatory diseases. The company is led by a small, experienced team and is supported by a network of industry partners, operating in a pre-revenue stage as it advances its platform towards clinical development.

EVO platform for developing novel, patent-protected immunomodulatory lipopeptides. These molecules are designed to be stable, non-toxic, and offer a selective anti-inflammatory effect, making them amenable to various formulations as standalone or steroid-sparing drugs.

The immunomodulatory drug space is highly competitive, dominated by biologics (e.g., anti-TNF, IL inhibitors) and an increasing number of small molecules and novel modalities. Evora's differentiation hinges on proving its lipopeptides offer a superior safety and efficacy profile, particularly as steroid-sparing agents, in a crowded field.